Pharmacogenomics in drug induced liver injury

Current Drug Metabolism

Volumn 10, Issue 9, 2009, Pages 956-970

  Andrade, Raúl J ^a,b   Agúndez, José A G ^c,d   Lucena, M Isabel ^a,b   Martínez, Carmen ^c,d   Cueto, Raquel ^a   García Martín, Elena ^c,d  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF EXTREMADURA   (Spain)

^d Red de Investigación de Reacciones Adversas a Alergenos Y Fármacos RIRAAF   (Spain)

Author keywords

Hepatotoxicity; Intolerance; Liver injury; Pharmacogenomics; Toxicogenomics

Indexed keywords

ACARBOSE; ALLOPURINOL; AMIODARONE; AMOXICILLIN; AMPICILLIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ARYLAMINE ACETYLTRANSFERASE; ASPARAGINASE; BENTAZEPAM; BROMFENAC; CLOMETHIAZOLE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DISULFIRAM; EBROTIDINE; FLUOXETINE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; UNINDEXED DRUG;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; CHOLESTASIS; DNA POLYMORPHISM; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG METABOLISM; ENZYME ACTIVITY; HEREDITY; HUMAN; LIVER CELL DAMAGE; LIVER INJURY; LIVER TOXICITY; NONHUMAN; PHARMACOGENOMICS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TOXIC HEPATITIS;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG-INDUCED LIVER INJURY; GENETIC PREDISPOSITION TO DISEASE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HUMANS; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; TOXICOGENETICS;

EID: 76749147800     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009790711805     Document Type: Review

References (208)

1. Temple, R. Policy developments in regulatory approval. Stat. Med., 2002, 21(19), 2939-2948.
2. Lee, W. M. Acute liver failure in the United States. Semin. Liver Dis., 2003, 23(3), 217-226.
3. Watkins, P. B.; Whitcomb, R. W. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med., 1998, 338(13), 916-917.
4. Gunawan, B.; Kaplowitz, N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab. Rev., 2004, 36(2), 301-312.
5. Lucena, M. I.; Andrade, R. J.; Kaplowitz, N.; Garcia-Cortes, M.; Fernandez, M. C.; Romero-Gomez, M.; Bruguera, M.; Hallal, H.; Robles-Diaz, M.; Rodriguez-Gonzalez, J. F.; Navarro, J. M.; Salmeron, J.; Martinez-Odriozola, P.; Perez-Alvarez, R.; Borraz, Y.; Hidalgo, R. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology, 2009, 49(6), 2001-2009.
6. Chalasani, N.; Fontana, R. J.; Bonkovsky, H. L.; Watkins, P. B.; Davern, T.; Serrano, J.; Yang, H.; Rochon, J. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology, 2008, 135(6), 1924-1934, 1934 e1921-1924.
7. Sgro, C.; Clinard, F.; Ouazir, K.; Chanay, H.; Allard, C.; Guilleminet, C.; Lenoir, C.; Lemoine, A.; Hillon, P. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology, 2002, 36(2), 451-455.
8. Meier, Y.; Cavallaro, M.; Roos, M.; Pauli-Magnus, C.; Folkers, G.; Meier, P. J.; Fattinger, K. Incidence of drug-induced liver injury in medical inpatients. Eur. J. Clin. Pharmacol., 2005, 61(2), 135-143.
9. Seguin, B.; Uetrecht, J. The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy Clin. Immunol., 2003, 3(4), 235-242.
10. Lammert, C.; Einarsson, S.; Saha, C.; Niklasson, A.; Bjornsson, E.; Chalasani, N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology, 2008, 47(6), 2003-2009.
11. Senior, J.R. What is idiosyncratic hepatotoxicity? What is it not? Hepatology, 2008, 47(6), 1813-1815.
12. Pessayre, D. Role of reactive metabolites in drug-induced hepatitis. J. Hepatol., 1995, 23 (Suppl 1)(16-24.
13. Gillette, J. R. Keynote address: man, mice, microsomes, metabolites, and mathematics 40 years after the revolution. Drug Metab. Rev., 1995, 27(1-2), 1-44.
14. Williams, D. P.; Kitteringham, N. R.; Naisbitt, D. J.; Pirmohamed, M.; Smith, D. A.; Park, B. K. Are chemically reactive metabolites responsible for adverse reactions to drugs? Curr. Drug Metab., 2002, 3(4), 351-366.
15. Walgren, J. L.; Mitchell, M. D.; Thompson, D. C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol., 2005, 35(4), 325-361.
16. Park, B. K.; Kitteringham, N. R.; Maggs, J. L.; Pirmohamed, M.; Williams, D. P. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol., 2005, 45(177-202.
17. Mitchell, J. R.; Jollow, D. J.; Potter, W. Z.; Davis, D. C.; Gillette, J. R.; Brodie, B. B. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther., 1973, 187(1), 185-194.
18. Phillips, K. A.; Veenstra, D. L.; Oren, E.; Lee, J. K.; Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA, 2001, 286(18), 2270-2279.
19. Xu, C.; Li, C. Y.; Kong, A. N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res., 2005, 28(3), 249-268.
20. Kaplowitz, N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov., 2005, 4(6), 489-499.
21. Njoku, D. B.; Greenberg, R. S.; Bourdi, M.; Borkowf, C. B.; Dake, E. M.; Martin, J. L.; Pohl, L. R. Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth. Analg., 2002, 94(2), 243-249, table of contents.
22. Aithal, G. P. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Expert. Opin. Drug Saf., 2004, 3(6), 519-523.
23. Vergani, D.; Mieli-Vergani, G.; Alberti, A.; Neuberger, J.; Eddleston, A. L.; Davis, M.; Williams, R. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med., 1980, 303(2), 66-71.
24. nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999.
25. Bourdi, M.; Tinel, M.; Beaune, P. H.; Pessayre, D. Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol. Pharmacol., 1994, 45(6), 1287-1295.
26. Daly, A. K.; Donaldson, P. T.; Bhatnagar, P.; Shen, Y.; Pe'er, I.; Floratos, A.; Daly, M. J.; Goldstein, D. B.; John, S.; Nelson, M. R.; Graham, J.; Park, B. K.; Dillon, J. F.; Bernal, W.; Cordell, H. J.; Pirmohamed, M.; Aithal, G. P.; Day, C. P. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet., 2009, 41(7), 816-819.
27. Mallal, S.; Nolan, D.; Witt, C.; Masel, G.; Martin, A. M.; Moore, C.; Sayer, D.; Castley, A.; Mamotte, C.; Maxwell, D.; James, I.; Christiansen, F. T. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 2002, 359(9308), 727-732.
28. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol., 1994, 12(991-1045.
29. Uetrecht, J. Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol., 2008, 21(1), 84-92.
30. Matzinger, P. Friendly and dangerous signals: is the tissue in control? Nat. Immunol., 2007, 8(1), 11-13.
31. Kaplowitz, N. Drug-induced liver injury. Clin. Infect. Dis., 2004, 38 (Suppl 2)(S44-48.
32. Berson, A.; De Beco, V.; Letteron, P.; Robin, M. A.; Moreau, C.; El Kahwaji, J.; Verthier, N.; Feldmann, G.; Fromenty, B.; Pessayre, D. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology, 1998, 114(4), 764-774.
33. Pessayre, D.; Berson, A.; Fromenty, B.; Mansouri, A. Mitochondria in steatohepatitis. Semin. Liver Dis., 2001, 21(1), 57-69.
34. Pessayre, D.; Haouzi, D.; Fau, D.; Robin, M. A.; Mansouri, A.; Berson, A. Withdrawal of life support, altruistic suicide, fratricidal killing and euthanasia by lymphocytes: different forms of drug-induced hepatic apoptosis. J. Hepatol., 1999, 31(4), 760-770.
35. Boelsterli, U. A.; Lim, P. L. Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol., 2007, 220(1), 92-107.
36. Ong, M. M.; Latchoumycandane, C.; Boelsterli, U. A. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol. Sci., 2007, 97(1), 205-213.
37. Fujimoto, K.; Kumagai, K.; Ito, K.; Arakawa, S.; Ando, Y.; Oda, S.; Yamoto, T.; Manabe, S. Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen. Toxicol. Pathol., 2009, 37(2), 193-200.
38. Andrade, R. J.; Lucena, M. I.; Fernandez, M. C.; Pelaez, G.; Pachkoria, K.; Garcia-Ruiz, E.; Garcia-Munoz, B.; Gonzalez-Grande, R.; Pizarro, A.; Duran, J. A.; Jimenez, M.; Rodrigo, L.; Romero-Gomez, M.; Navarro, J. M.; Planas, R.; Costa, J.; Borras, A.; Soler, A.; Salmeron, J.; Martin-Vivaldi, R. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology, 2005, 129(2), 512-521.
39. Bjornsson, E.; Olsson, R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology, 2005, 42(2), 481-489.
40. Andrade, R. J.; Lucena, M. I.; Martin-Vivaldi, R.; Fernandez, M. C.; Nogueras, F.; Pelaez, G.; Gomez-Outes, A.; Garcia-Escano, M. D.; Bellot, V.; Hervas, A.; Cardenas, F.; Bermudez, F.; Romero, M.; Salmeron, J. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J. Hepatol., 1999, 31(4), 641-646.
41. Lucena, M. I.; Andrade, R. J.; Rodrigo, L.; Salmeron, J.; Alvarez, A.; Lopez-Garrido, M. J.; Camargo, R.; Alcantara, R. Trovafloxacin-induced acute hepatitis. Clin. Infect. Dis., 2000, 30(2), 400-401.
42. Lucena, M. I.; Carvajal, A.; Andrade, R. J.; Velasco, A. Antidepressant-induced hepatotoxicity. Expert. Opin. Drug Saf., 2003, 2(3), 249-262.
43. Andrade, R. J.; Lucena, M. I.; Alcantara, R.; Fraile, J. M. Bentazepam-associated chronic liver disease. Lancet, 1994, 343(8901), 860.
44. Spahn-Langguth, H.; Li, C.; Benet, L. In: Role of Acyl glucururonides. Drug-Induced Liver Disease, Kaplowitz N.; DeLeve, L., Eds.; New York: Informa Healthcare.
45. Gronhagen-Riska, C.; Hellstrom, P. E.; Froseth, B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am. Rev. Respir. Dis., 1978, 118(3), 461-466.
46. Garcia Rodriguez, L. A.; Stricker, B. H.; Zimmerman, H. J. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch. Intern. Med., 1996, 156(12), 1327-1332.
47. Hussaini, S. H.; O'Brien, C. S.; Despott, E. J.; Dalton, H. R. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur. J. Gastroenterol. Hepatol., 2007, 19(1), 15-20.
48. Friis, H.; Andreasen, P. B. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J. Intern. Med., 1992, 232(2), 133-138.
49. Watkins, P. B.; Seeff, L. B. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology, 2006, 43(3), 618-631.
50. De Valle, M. B.; Av Klinteberg, V.; Alem, N.; Olsson, R.; Bjornsson, E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment. Pharmacol. Ther., 2006, 24(8), 1187-1195.
51. Ibanez, L.; Perez, E.; Vidal, X.; Laporte, J. R. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J. Hepatol., 2002, 37(5), 592-600.
52. Russo, M. W.; Galanko, J. A.; Shrestha, R.; Fried, M. W.; Watkins, P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl., 2004, 10(8), 1018-1023.
53. Danan, G.; Benichou, C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol., 1993, 46(11), 1323-1330.
54. de Abajo, F. J.; Montero, D.; Madurga, M.; Garcia Rodriguez, L. A. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br. J. Clin. Pharmacol., 2004, 58(1), 71-80.
55. Pessayre, D.; Bentata, M.; Degott, C.; Nouel, O.; Miguet, J. P.; Rueff, B.; Benhamou, J. P. Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction. Gastroenterology, 1977, 72(2), 284-289.
56. Bonfanti, P.; Landonio, S.; Ricci, E.; Martinelli, C.; Fortuna, P.; Faggion, I.; Quirino, T. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr., 2001, 27(3), 316-318.
57. Lewis, J. H. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert. Opin. Drug Saf., 2002, 1(2), 159-172.
58. Rosenberg, P.; Urwitz, H.; Johannesson, A.; Ros, A. M.; Lindholm, J.; Kinnman, N.; Hultcrantz, R. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J. Hepatol., 2007, 46(6), 1111-1118.
59. Benichou, C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J. Hepatol., 1990, 11(2), 272-276.
60. Andrade, R. J.; Lucena, M. I.; Kaplowitz, N.; Garcia-Munoz, B.; Borraz, Y.; Pachkoria, K.; Garcia-Cortes, M.; Fernandez, M. C.; Pelaez, G.; Rodrigo, L.; Duran, J. A.; Costa, J.; Planas, R.; Barriocanal, A.; Guarner, C.; Romero-Gomez, M.; Munoz-Yague, T.; Salmeron, J.; Hidalgo, R. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology, 2006, 44(6), 1581-1588.
61. Navarro, V. J.; Senior, J. R. Drug-related hepatotoxicity. N. Engl. J. Med., 2006, 354(7), 731-739.
62. Pachkoria, K.; Lucena, M. I.; Crespo, E.; Ruiz-Cabello, F.; Lopez-Ortega, S.; Fernandez, M. A.; Romero-Gomez, M.; Madrazo, A.; Duran, J. A.; de Dios, A. M.; Borraz, Y.; Navarro, J. M.; Andrade, R. J. Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J. Hepatol., 2008, 49(1), 107-114.
63. Russo, M. W.; Watkins, P. B. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology, 2004, 126(5), 1477-1480.
64. Andrade, R. J.; Lucena, M. I.; Alonso, A.; Garcia-Cortes, M.; Garcia-Ruiz, E.; Benitez, R.; Fernandez, M. C.; Pelaez, G.; Romero, M.; Corpas, R.; Duran, J. A.; Jimenez, M.; Rodrigo, L.; Nogueras, F.; Martin-Vivaldi, R.; Navarro, J. M.; Salmeron, J.; de la Cuesta, F. S.; Hidalgo, R. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology, 2004, 39(6), 1603-1612.
65. Bjornsson, E.; Davidsdottir, L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J. Hepatol., 2009, 50(3), 511-517.
66. Bjornsson, E.; Kalaitzakis, E.; Av Klinteberg, V.; Alem, N.; Olsson, R. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment. Pharmacol. Ther., 2007, 26(1), 79-85.
67. Ingelman-Sundberg, M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med, 2001, 250(3), 186-200.
68. Giacomini, K. M.; Krauss, R. M.; Roden, D. M.; Eichelbaum, M.; Hayden, M. R.; Nakamura, Y. When good drugs go bad. Nature, 2007, 446(7139), 975-977.
69. Teml, A.; Schwab, M.; Hommes, D. W.; Almer, S.; Lukas, M.; Feichtenschlager, T.; Florin, T.; Seiderer, J.; Petritsch, W.; Bokemeyer, B.; Kreisel, W.; Herrlinger, K. R.; Knoflach, P.; Bonaz, B.; Klugmann, T.; Herfarth, H.; Pedarnig, N.; Reinisch, W. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien. Klin. Wochenschr., 2007, 119(17-18), 519-526.
70. Agundez, J. A.; Garcia-Martin, E.; Martinez, C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert. Opin. Drug Metab. Toxicol., 2009, 5(6), 607-620.
71. Zhou, S. F.; Chan, E.; Zhou, Z. W.; Xue, C. C.; Lai, X.; Duan, W. Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2. Curr. Drug Metab., 2009.
72. Chen, Y.; Goldstein, J. A. The transcriptional regulation of the human CYP2C genes. Curr. Drug Metab., 2009, 10(6), 567-578.
73. Daily, E. B.; Aquilante, C. L. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics, 2009, 10(9), 1489-1510.
74. Zhou, S. F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet., 2009, 48(11), 689-723.
75. Chico, L. K.; Behanna, H. A.; Hu, W.; Zhong, G.; Roy, S. M.; Watterson, D. M. Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database. Drug Metab. Dispos., 2009, 37(11), 2204-2211.
76. Zhou, S. F.; Zhou, Z. W.; Yang, L. P.; Cai, J. P. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr. Med. Chem., 2009, 16(27), 3480-3675.
77. Zhou, S. F.; Liu, J. P.; Chowbay, B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev., 2009, 41(2), 89-295.
78. Kato, M. Intestinal first-pass metabolism of CYP3A4 substrates. Drug Metab. Pharmacokinet., 2008, 23(2), 87-94.
79. Liu, Y. T.; Hao, H. P.; Liu, C. X.; Wang, G. J.; Xie, H. G. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab. Rev., 2007, 39(4), 699-721.
80. Garcia-Martin, E.; Martinez, C.; Tabares, B.; Frias, J.; Agundez, J. A. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther., 2004, 76(2), 119-127.
81. Martinez, C.; Garcia-Martin, E.; Blanco, G.; Gamito, F. J.; Ladero, J. M.; Agundez, J. A. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br. J. Clin. Pharmacol., 2005, 59(1), 62-69.
82. Garcia-Martin, E.; Pizarro, R. M.; Martinez, C.; Gutierrez-Martin, Y.; Perez, G.; Jover, R.; Agundez, J. A. Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. Pharmacogenomics, 2006, 7(4), 575-585.
83. Blanco, G.; Martinez, C.; Ladero, J. M.; Garcia-Martin, E.; Taxonera, C.; Gamito, F. G.; Diaz-Rubio, M.; Agundez, J. A. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet. Genomics, 2008, 18(1), 37-43.
84. Martinez, C.; Blanco, G.; Ladero, J. M.; Garcia-Martin, E.; Taxonera, C.; Gamito, F. G.; Diaz-Rubio, M.; Agundez, J. A. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br. J. Pharmacol., 2004, 141(2), 205-208.
85. Restrepo, J. G.; Garcia-Martin, E.; Martinez, C.; Agundez, J. A. Polymorphic drug metabolism in anaesthesia. Curr. Drug Metab., 2009, 10(3), 236-246.
86. Martinez, C.; Garcia-Martin, E.; Pizarro, R. M.; Garcia-Gamito, F. J.; Agundez, J. A. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br. J. Cancer, 2002, 87(6), 681-686.
87. Garcia-Martin, E.; Martinez, C.; Pizarro, R. M.; Garcia-Gamito, F. J.; Gullsten, H.; Raunio, H.; Agundez, J. A. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin. Pharmacol. Ther., 2002, 71(3), 196-204.
88. Guengerich, F. P.; Parikh, A.; Turesky, R. J.; Josephy, P. D. Interindividual differences in the metabolism of environmental toxicants: cytochrome P450 1A2 as a prototype. Mutat. Res., 1999, 428(1-2), 115-124.
89. Zhou, H.; Josephy, P. D.; Kim, D.; Guengerich, F. P. Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch. Biochem. Biophys., 2004, 422(1), 23-30.
90. Chevalier, D.; Cauffiez, C.; Allorge, D.; Lo-Guidice, J. M.; Lhermitte, M.; Lafitte, J. J.; Broly, F. Five novel natural allelic variants-951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)-of the human CYP1A2 gene in a French Caucasian population. Hum. Mutat., 2001, 17(4), 355-356.
91. Nakajima, M.; Yokoi, T.; Mizutani, M.; Kinoshita, M.; Funayama, M.; Kamataki, T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem., 1999, 125(4), 803-808.
92. Kuribayashi, S.; Goto, K.; Naito, S.; Kamataki, T.; Yamazaki, H. Human cytochrome P450 1A2 involvement in the formation of reactive metabolites from a species-specific hepatotoxic pyrazolopyrimidine derivative, 5-n-butyl-7-(3,4,5- trimethoxybenzoylamino) pyrazolo[1,5-a]pyrimidine. Chem. Res. Toxicol., 2009, 22(2), 323-331.
93. Ahmadizadeh, M.; Kuo, C. H.; Echt, R.; Hook, J. B. Effect of polybrominated biphenyls, beta-naphthoflavone and phenobarbital on arylhydrocarbon hydroxylase activities and chloroform-induced nephrotoxicity and hepatotoxicity in male C57BL/6J and DBA/2J mice. Toxicology, 1984, 31(3-4), 343-352.
94. Jacob, R. M.; Johnstone, E. C.; Neville, M. J.; Walton, R. T. Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin. Chem., 2004, 50(8), 1372-1377.
95. Frazer, K. A.; Ballinger, D. G.; Cox, D. R.; Hinds, D. A.; Stuve, L. L.; Gibbs, R. A.; Belmont, J. W.; Boudreau, A.; Hardenbol, P.; Leal, S. M.; Pasternak, S.; Wheeler, D. A.; Willis, T. D.; Yu, F.; Yang, H.; Zeng, C.; Gao, Y.; Hu, H.; Hu, W.; Li, C.; Lin, W.; Liu, S.; Pan, H.; Tang, X.; Wang, J.; Wang, W.; Yu, J.; Zhang, B.; Zhang, Q.; Zhao, H.; Zhou, J.; Gabriel, S. B.; Barry, R.; Blumenstiel, B.; Camargo, A.; Defelice, M.; Faggart, M.; Goyette, M.; Gupta, S.; Moore, J.; Nguyen, H.; Onofrio, R. C.; Parkin, M.; Roy, J.; Stahl, E.; Winchester, E.; Ziaugra, L.; Altshuler, D.; Shen, Y.; Yao, Z.; Huang, W.; Chu, X.; He, Y.; Jin, L.; Liu, Y.; Sun, W.; Wang, H.; Wang, Y.; Xiong, X.; Xu, L.; Waye, M. M.; Tsui, S. K.; Xue, H.; Wong, J. T.; Galver, L. M.; Fan, J. B.; Gunderson, K.; Murray, S. S.; Oliphant, A. R.; Chee, M. S.; Montpetit, A.; Chagnon, F.; Ferretti, V.; Leboeuf, M.; Olivier, J. F.; Phillips, M. S.; Roumy, S.; Sallee, C.; Verner, A.; Hudson, T. J.; Kwok, P. Y.; Cai, D.; Koboldt, D. C.; Miller, R. D.; Pawlikowska, L.; Taillon-Miller, P.; Xiao, M.; Tsui, L. C.; Mak, W.; Song, Y. Q.; Tam, P. K.; Nakamura, Y.; Kawaguchi, T.; Kitamoto, T.; Morizono, T.; Nagashima, A.; Ohnishi, Y.; Sekine, A.; Tanaka, T.; Tsunoda, T.; Deloukas, P.; Bird, C. P.; Delgado, M.; Dermitzakis, E. T.; Gwilliam, R.; Hunt, S.; Morrison, J.; Powell, D.; Stranger, B. E.; Whittaker, P.; Bentley, D. R.; Daly, M. J.; de Bakker, P. I.; Barrett, J.; Chretien, Y. R.; Maller, J.; McCarroll, S.; Patterson, N.; Pe'er, I.; Price, A.; Purcell, S.; Richter, D. J.; Sabeti, P.; Saxena, R.; Schaffner, S. F.; Sham, P. C.; Varilly, P.; Stein, L. D.; Krishnan, L.; Smith, A. V.; Tello-Ruiz, M. K.; Thorisson, G. A.; Chakravarti, A.; Chen, P. E.; Cutler, D. J.; Kashuk, C. S.; Lin, S.; Abecasis, G. R.; Guan, W.; Li, Y.; Munro, H. M.; Qin, Z. S.; Thomas, D. J.; McVean, G.; Auton, A.; Bottolo, L.; Cardin, N.; Eyheramendy, S.; Freeman, C.; Marchini, J.; Myers, S.; Spencer, C.; Stephens, M.; Donnelly, P.; Cardon, L. R.; Clarke, G.; Evans, D. M.; Morris, A. P.; Weir, B. S.; Mullikin, J. C.; Sherry, S. T.; Feolo, M.; Skol, A.; Zhang, H.; Matsuda, I.; Fukushima, Y.; Macer, D. R.; Suda, E.; Rotimi, C. N.; Adebamowo, C. A.; Ajayi, I.; Aniagwu, T.; Marshall, P. A.; Nkwodimmah, C.; Royal, C. D.; Leppert, M. F.; Dixon, M.; Peiffer, A.; Qiu, R.; Kent, A.; Kato, K.; Niikawa, N.; Adewole, I. F.; Knoppers, B. M.; Foster, M. W.; Clayton, E. W.; Watkin, J.; Muzny, D.; Nazareth, L.; Sodergren, E.; Weinstock, G. M.; Yakub, I.; Birren, B. W.; Wilson, R. K.; Fulton, L. L.; Rogers, J.; Burton, J.; Carter, N. P.; Clee, C. M.; Griffiths, M.; Jones, M. C.; McLay, K.; Plumb, R. W.; Ross, M. T.; Sims, S. K.; Willey, D. L.; Chen, Z.; Han, H.; Kang, L.; Godbout, M.; Wallenburg, J. C.; L'Archeveque, P.; Bellemare, G.; Saeki, K.; An, D.; Fu, H.; Li, Q.; Wang, Z.; Wang, R.; Holden, A. L.; Brooks, L. D.; McEwen, J. E.; Guyer, M. S.; Wang, V. O.; Peterson, J. L.; Shi, M.; Spiegel, J.; Sung, L. M.; Zacharia, L. F.; Collins, F. S.; Kennedy, K.; Jamieson, R.; Stewart, J. A second generation human haplotype map of over 3.1 million SNPs. Nature, 2007, 449(7164), 851-861.
96. Garcia-Martin, E.; Martinez, C.; Ladero, J. M.; Gamito, F. J.; Agundez, J. A. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur. J. Clin. Pharmacol., 2001, 57(1), 47-49.
97. Agundez, J. A. Cytochrome P450 gene polymorphism and cancer. Curr. Drug Metab., 2004, 5(3), 211-224.
98. Agundez, J. A.; Martinez, C.; Garcia-Martin, E.; Ladero, J. M. Cytochrome P450 CYP2C9 polymorphism and NSAID-related acute gastrointestinal bleeding. Gastroenterology, 2007, 133(6), 2071-2072; author reply 2072-2073.
99. Garcia-Martin, E.; Martinez, C.; Ladero, J. M.; Gamito, F. J.; Rodriguez-Lescure, A.; Agundez, J. A. Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. Cancer Lett., 2002, 180(1), 41-46.
100. Martinez, C.; Garcia-Martin, E.; Ladero, J. M.; Sastre, J.; Garcia-Gamito, F.; Diaz-Rubio, M.; Agundez, J. A. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis, 2001, 22(8), 1323-1326.
101. Li, Y.; Dai, G. W.; Li, Y.; Liu, G. T. [Effect of bicyclol on acetaminophen-induced hepatotoxicity: energetic metabolism and mitochondrial injury in acetaminophen-intoxicated mice]. Yao Xue Xue Bao, 2001, 36(10), 723-726.
102. Soyama, A.; Hanioka, N.; Saito, Y.; Murayama, N.; Ando, M.; Ozawa, S.; Sawada, J. Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacol. Toxicol., 2002, 91(4), 174-178.
103. Bahadur, N.; Leathart, J. B.; Mutch, E.; Steimel-Crespi, D.; Dunn, S. A.; Gilissen, R.; Houdt, J. V.; Hendrickx, J.; Mannens, G.; Bohets, H.; Williams, F. M.; Armstrong, M.; Crespi, C. L.; Daly, A. K. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem. Pharmacol., 2002, 64(11), 1579-1589.
104. Totah, R. A.; Rettie, A. E. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther., 2005, 77(5), 341-352.
105. Levin, M. D.; den Hollander, J. G.; van der Holt, B.; Rijnders, B. J.; van Vliet, M.; Sonneveld, P.; van Schaik, R. H. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J. Antimicrob. Chemother., 2007, 60(5), 1104-1107.
106. Ho, P. C.; Abbott, F. S.; Zanger, U. M.; Chang, T. K. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J., 2003, 3(6), 335-342.
107. Sevilla-Mantilla, C.; Ortega, L.; Agundez, J. A.; Fernandez-Gutierrez, B.; Ladero, J. M.; Diaz-Rubio, M. Leflunomide-induced acute hepatitis. Dig. Liver Dis., 2004, 36(1), 82-84.
108. Aithal, G. P.; Day, C. P.; Leathart, J. B.; Daly, A. K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics, 2000, 10(6), 511-518.
109. Pachkoria, K.; Lucena, M. I.; Ruiz-Cabello, F.; Crespo, E.; Cabello, M. R.; Andrade, R. J. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br. J. Pharmacol., 2007, 150(6), 808-815.
110. Tang, W. The metabolism of diclofenac - enzymology and toxicology perspectives. Curr. Drug Metab., 2003, 4(4), 319-329.
111. Daly, A. K.; Aithal, G. P.; Leathart, J. B.; Swainsbury, R. A.; Dang, T. S.; Day, C. P. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology, 2007, 132(1), 272-281.
112. Yasar, U.; Lundgren, S.; Eliasson, E.; Bennet, A.; Wiman, B.; de Faire, U.; Rane, A. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem. Biophys. Res. Commun., 2002, 299(1), 25-28.
113. Garcia-Martin, E.; Martinez, C.; Ladero, J. M.; Agundez, J. A. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol. Diagn. Ther., 2006, 10(1), 29-40.
114. Martinez, C.; Garcia-Martin, E.; Alonso-Navarro, H.; Jimenez-Jimenez, F. J.; Benito-Leon, J.; Garcia-Ferrer, I.; Vazquez-Torres, P.; Puertas, I.; Zurdo, J. M.; Lopez-Alburquerque, T.; Agundez, J. A. Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. Neuromol. Med., 2007, 9(2), 195-204.
115. Alonso-Navarro, H.; Martinez, C.; Garcia-Martin, E.; Benito-Leon, J.; Garcia-Ferrer, I.; Vazquez-Torres, P.; Puertas, I.; Lopez-Alburquerque, T.; Agundez, J. A.; Jimenez-Jimenez, F. J. CYP2C19 polymorphism and risk for essential tremor. Eur. Neurol., 2006, 56(2), 119-123.
116. Desta, Z.; Zhao, X.; Shin, J. G.; Flockhart, D. A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet., 2002, 41(12), 913-958.
117. Horsmans, Y.; Lannes, D.; Pessayre, D.; Larrey, D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. J. Hepatol., 1994, 21(6), 1075-1079.
118. Bradford, L. D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics, 2002, 3(2), 229-243.
119. Ledesma, M. C.; Agundez, J. A. Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication. Clin. Chem., 2005, 51(6), 939-943.
120. Ellingrod, V. L.; Schultz, S. K.; Arndt, S. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr. Genet., 2000, 10(1), 9-11.
121. Chou, W. H.; Yan, F. X.; de Leon, J.; Barnhill, J.; Rogers, T.; Cronin, M.; Pho, M.; Xiao, V.; Ryder, T. B.; Liu, W. W.; Teiling, C.; Wedlund, P. J. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J. Clin. Psychopharmacol., 2000, 20(2), 246-251.
122. Andreassen, O. A.; MacEwan, T.; Gulbrandsen, A. K.; McCreadie, R. G.; Steen, V. M. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl), 1997, 131(2), 174-179.
123. Schillevoort, I.; de Boer, A.; van der Weide, J.; Steijns, L. S.; Roos, R. A.; Jansen, P. A.; Leufkens, H. G. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics, 2002, 12(3), 235-240.
124. Morgan, M. Y.; Reshef, R.; Shah, R. R.; Oates, N. S.; Smith, R. L.; Sherlock, S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut, 1984, 25(10), 1057-1064.
125. Farrell, G. C. Drugs and steatohepatitis. Semin. Liver Dis., 2002, 22(2), 185-194.
126. Kim, S. H.; Kim, S. H.; Bahn, J. W.; Kim, Y. K.; Chang, Y. S.; Shin, E. S.; Kim, Y. S.; Park, J. S.; Kim, B. H.; Jang, I. J.; Song, J.; Kim, S. H.; Park, H. S.; Min, K. U.; Jee, Y. K. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics, 2009, 10(11), 1767-1779.
127. Guengerich, F. P.; Kim, D. H.; Iwasaki, M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol., 1991, 4(2), 168-179.
128. Sinclair, J.; Jeffery, E.; Wrighton, S.; Kostrubsky, V.; Szakacs, J.; Wood, S.; Sinclair, P. Alcohol-mediated increases in acetaminophen hepatotoxicity: role of CYP2E and CYP3A. Biochem. Pharmacol., 1998, 55(10), 1557-1565.
129. Gonzalez, F. J. The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab. Dispos., 2007, 35(1), 1-8.
130. Zaher, H.; Buters, J. T.; Ward, J. M.; Bruno, M. K.; Lucas, A. M.; Stern, S. T.; Cohen, S. D.; Gonzalez, F. J. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol. Appl. Pharmacol., 1998, 152(1), 193-199.
131. Wong, F. W.; Chan, W. Y.; Lee, S. S. Resistance to carbon tetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol. Appl. Pharmacol., 1998, 153(1), 109-118.
132. Fleischner, G. M.; Morecki, R.; Hanaichi, T.; Hayashi, H.; Quintana, N.; Sternlieb, I. Light- and electron-microscopical study of a case of gold salt-induced hepatotoxicity. Hepatology, 1991, 14(3), 422-425.
133. Huang, Y. S.; Chern, H. D.; Su, W. J.; Wu, J. C.; Chang, S. C.; Chiang, C. H.; Chang, F. Y.; Lee, S. D. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology, 2003, 37(4), 924-930.
134. Vuilleumier, N.; Rossier, M. F.; Chiappe, A.; Degoumois, F.; Dayer, P.; Mermillod, B.; Nicod, L.; Desmeules, J.; Hochstrasser, D. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur. J. Clin. Pharmacol., 2006, 62(6), 423-429.
135. Cho, H. J.; Koh, W. J.; Ryu, Y. J.; Ki, C. S.; Nam, M. H.; Kim, J. W.; Lee, S. Y. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb), 2007, 87(6), 551-556.
136. Yamada, S.; Tang, M.; Richardson, K.; Halaschek-Wiener, J.; Chan, M.; Cook, V. J.; Fitzgerald, J. M.; Elwood, R. K.; Brooks-Wilson, A.; Marra, F. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics, 2009, 10(9), 1433-1445.
137. Sun, F.; Chen, Y.; Xiang, Y.; Zhan, S. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int. J. Tuberc. Lung Dis., 2008, 12(9), 994-1002.
138. Jeong, H. G.; Park, H. Y. The prevention of carbon tetrachloride-induced hepatotoxicity in mice by alpha-hederin: inhibiton of cytochrome P450 2E1 expression. Biochem. Mol. Biol. Int., 1998, 45(1), 163-170.
139. Jeong, H. G. Inhibition of cytochrome P450 2E1 expression by oleanolic acid: hepatoprotective effects against carbon tetrachloride-induced hepatic injury. Toxicol. Lett., 1999, 105(3), 215-222.
140. Liu, L. G.; Yan, H.; Yao, P.; Zhang, W.; Zou, L. J.; Song, F. F.; Li, K.; Sun, X. F. CYP2E1-dependent hepatotoxicity and oxidative damage after ethanol administration in human primary hepatocytes. World J. Gastroenterol., 2005, 11(29), 4530-4535.
141. Oneta, C. M.; Lieber, C. S.; Li, J.; Ruttimann, S.; Schmid, B.; Lattmann, J.; Rosman, A. S.; Seitz, H. K. Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. J. Hepatol., 2002, 36(1), 47-52.
142. Hernandez-Boussard, T.; Whirl-Carrillo, M.; Hebert, J. M.; Gong, L.; Owen, R.; Gong, M.; Gor, W.; Liu, F.; Truong, C.; Whaley, R.; Woon, M.; Zhou, T.; Altman, R. B.; Klein, T. E. The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge. Nucleic Acids Res., 2008, 36(Database issue), D913-918.
143. Zhou, S. F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab., 2008, 9(4), 310-322.
144. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 1994, 270(1), 414-423.
145. Rodriguez-Antona, C.; Sayi, J. G.; Gustafsson, L. L.; Bertilsson, L.; Ingelman-Sundberg, M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem. Biophys. Res. Commun., 2005, 338(1), 299-305.
146. Floyd, M. D.; Gervasini, G.; Masica, A. L.; Mayo, G.; George, A. L., Jr.; Bhat, K.; Kim, R. B.; Wilkinson, G. R. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics, 2003, 13(10), 595-606.
147. Farkas, D.; Greenblatt, D. J. Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert. Opin. Drug Metab. Toxicol., 2008, 4(4), 381-393.
148. Burk, O.; Koch, I.; Raucy, J.; Hustert, E.; Eichelbaum, M.; Brockmoller, J.; Zanger, U. M.; Wojnowski, L. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J. Biol. Chem., 2004, 279(37), 38379-38385.
149. Brandin, H.; Viitanen, E.; Myrberg, O.; Arvidsson, A. K. Effects of herbal medicinal products and food supplements on induction of CYP1A2, CYP3A4 and MDR1 in the human colon carcinoma cell line LS180. Phytother. Res., 2007, 21(3), 239-244.
150. Cheng, J.; Ma, X.; Krausz, K. W.; Idle, J. R.; Gonzalez, F. J. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab. Dispos., 2009, 37(8), 1611-1621.
151. Masubuchi, Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab. Pharmacokinet., 2006, 21(5), 347-356.
152. Kassahun, K.; Pearson, P. G.; Tang, W.; McIntosh, I.; Leung, K.; Elmore, C.; Dean, D.; Wang, R.; Doss, G.; Baillie, T. A. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol., 2001, 14(1), 62-70.
153. Lakehal, F.; Dansette, P. M.; Becquemont, L.; Lasnier, E.; Delelo, R.; Balladur, P.; Poupon, R.; Beaune, P. H.; Housset, C. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem. Res. Toxicol., 2001, 14(6), 694-701.
154. Haas, D. W.; Bartlett, J. A.; Andersen, J. W.; Sanne, I.; Wilkinson, G. R.; Hinkle, J.; Rousseau, F.; Ingram, C. D.; Shaw, A.; Lederman, M. M.; Kim, R. B. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin. Infect. Dis., 2006, 43(6), 783-786.
155. Meyer, U. A.; Zanger, U. M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol., 1997, 37(269-296.
156. Agundez, J. A. N-acetyltransferases: lessons learned from eighty years of research. Curr. Drug Metab., 2008, 9(6), 463-464.
157. Agundez, J. A. Polymorphisms of human N-acetyltransferases and cancer risk. Curr. Drug Metab., 2008, 9(6), 520-531.
158. Hickman, D.; Risch, A.; Buckle, V.; Spurr, N. K.; Jeremiah, S. J.; McCarthy, A.; Sim, E. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem. J., 1994, 297 ( Pt 3)(441-445.
159. Walraven, J. M.; Zang, Y.; Trent, J. O.; Hein, D. W. Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr. Drug Metab., 2008, 9(6), 471-486.
160. Hein, D. W. N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert. Opin. Drug Metab. Toxicol., 2009, 5(4), 353-366.
161. Agundez, J. A.; Golka, K.; Martinez, C.; Selinski, S.; Blaszkewicz, M.; Garcia-Martin, E. Unraveling ambiguous NAT2 genotyping data. Clin. Chem., 2008, 54(8), 1390-1394.
162. Garcia-Martin, E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr. Drug Metab., 2008, 9(6), 487-497.
163. Makarova, S. I. Human N-acetyltransferases and drug-induced hepatotoxicity. Curr. Drug Metab., 2008, 9(6), 538-545.
164. Mitchell, J. R.; Zimmerman, H. J.; Ishak, K. G.; Thorgeirsson, U. P.; Timbrell, J. A.; Snodgrass, W. R.; Nelson, S. D. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann. Intern. Med., 1976, 84(2), 181-192.
165. Ryan, D. E.; Ramanathan, L.; Iida, S.; Thomas, P. E.; Haniu, M.; Shively, J. E.; Lieber, C. S.; Levin, W. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J. Biol. Chem., 1985, 260(10), 6385-6393.
166. Ellard, G. A. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin. Pharmacol. Ther., 1976, 19(5 Pt 2), 610-625.
167. Lauterburg, B. H.; Smith, C. V.; Todd, E. L.; Mitchell, J. R. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J. Pharmacol. Exp. Ther., 1985, 235(3), 566-570.
168. Huang, Y. S.; Chern, H. D.; Su, W. J.; Wu, J. C.; Lai, S. L.; Yang, S. Y.; Chang, F. Y.; Lee, S. D. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology, 2002, 35(4), 883-889.
169. Bozok Cetintas, V.; Erer, O. F.; Kosova, B.; Ozdemir, I.; Topcuoglu, N.; Aktogu, S.; Eroglu, Z. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. Tuberk Toraks, 2008, 56(1), 81-86.
170. Higuchi, N.; Tahara, N.; Yanagihara, K.; Fukushima, K.; Suyama, N.; Inoue, Y.; Miyazaki, Y.; Kobayashi, T.; Yoshiura, K.; Niikawa, N.; Wen, C. Y.; Isomoto, H.; Shikuwa, S.; Omagari, K.; Mizuta, Y.; Kohno, S.; Tsukamoto, K. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of antituberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J. Gastroenterol., 2007, 13(45), 6003-6008.
171. Ohno, M.; Yamaguchi, I.; Yamamoto, I.; Fukuda, T.; Yokota, S.; Maekura, R.; Ito, M.; Yamamoto, Y.; Ogura, T.; Maeda, K.; Komuta, K.; Igarashi, T.; Azuma, J. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis., 2000, 4(3), 256-261.
172. Possuelo, L. G.; Castelan, J. A.; de Brito, T. C.; Ribeiro, A. W.; Cafrune, P. I.; Picon, P. D.; Santos, A. R.; Teixeira, R. L.; Gregianini, T. S.; Hutz, M. H.; Rossetti, M. L.; Zaha, A. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur. J. Clin. Pharmacol., 2008, 64(7), 673-681.
173. Roy, B.; Chowdhury, A.; Kundu, S.; Santra, A.; Dey, B.; Chakraborty, M.; Majumder, P. P. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J. Gastroenterol. Hepatol., 2001, 16(9), 1033-1037.
174. Hayes, J. D.; Flanagan, J. U.; Jowsey, I. R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol., 2005, 45(51-88.
175. Strange, R. C.; Spiteri, M. A.; Ramachandran, S.; Fryer, A. A. Glutathione-S-transferase family of enzymes. Mutat. Res., 2001, 482(1-2), 21-26.
176. Ladero, J. M.; Martinez, C.; Fernandez, J. M.; Martin, F.; Garcia-Martin, E.; Ropero, P.; Villegas, A.; Diaz-Rubio, M.; Agundez, J. A. Glutathione S-transferases pi 1, alpha 1 and M3 genetic polymorphisms and the risk of hepatocellular carcinoma in humans. Pharmacogenomics, 2007, 8(8), 895-899.
177. Ladero, J. M.; Martinez, C.; Garcia-Martin, E.; Fernandez-Arquero, M.; Lopez-Alonso, G.; de la Concha, E. G.; Diaz-Rubio, M.; Agundez, J. A. Polymorphisms of the glutathione S-transferases mu-1 (GSTM1) and theta-1 (GSTT1) and the risk of advanced alcoholic liver disease. Scand J. Gastroenterol., 2005, 40(3), 348-353.
178. Ladero, J. M.; Martinez, C.; Garcia-Martin, E.; Ropero, P.; Briceno, O.; Villegas, A.; Diaz-Rubio, M.; Agundez, J. A. Glutathione S-transferase M1 and T1 genetic polymorphisms are not related to the risk of hepatocellular carcinoma: a study in the Spanish population. Eur. J. Cancer., 2006, 42(1), 73-77.
179. Martinez, C.; Garcia-Martin, E.; Ladero, J. M.; Herraez, O.; Ortega, L.; Taxonera, C.; Suarez, A.; Diaz-Rubio, M.; Agundez, J. A. GSTT1 and GSTM1 null genotypes may facilitate hepatitis C virus infection becoming chronic. J. Infect. Dis., 2007, 195(9), 1320-1323.
180. Martinez, C.; Martin, F.; Fernandez, J. M.; Garcia-Martin, E.; Sastre, J.; Diaz-Rubio, M.; Agundez, J. A.; Ladero, J. M. Glutathione S-transferases mu 1, theta 1, pi 1, alpha 1 and mu 3 genetic polymorphisms and the risk of colorectal and gastric cancers in humans. Pharmacogenomics, 2006, 7(5), 711-718.
181. Lucena, M. I.; Andrade, R. J.; Martinez, C.; Ulzurrun, E.; Garcia-Martin, E.; Borraz, Y.; Fernandez, M. C.; Romero-Gomez, M.; Castiella, A.; Planas, R.; Costa, J.; Anzola, S.; Agundez, J. A. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology, 2008, 48(2), 588-596.
182. Huang, Y. S.; Su, W. J.; Huang, Y. H.; Chen, C. Y.; Chang, F. Y.; Lin, H. C.; Lee, S. D. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J. Hepatol., 2007, 47(1), 128-134.
183. Leiro, V.; Fernandez-Villar, A.; Valverde, D.; Constenla, L.; Vazquez, R.; Pineiro, L.; Gonzalez-Quintela, A. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int., 2008, 28(6), 835-839.
184. Watanabe, I.; Tomita, A.; Shimizu, M.; Sugawara, M.; Yasumo, H.; Koishi, R.; Takahashi, T.; Miyoshi, K.; Nakamura, K.; Izumi, T.; Matsushita, Y.; Furukawa, H.; Haruyama, H.; Koga, T. A study to survey susceptible genetic factors responsible for troglitazone-ssociated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther., 2003, 73(5), 435-455.
185. Ueda, K.; Ishitsu, T.; Seo, T.; Ueda, N.; Murata, T.; Hori, M.; Nakagawa, K. Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics, 2007, 8(5), 435-442.
186. Lucena, M. I.; Martinez, C.; Andrade, R. J.; Garcia-Martin, E.; Ulzurrun, E.; Agundez, J. A. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Reply. Hepatology, 2009, 49(5), 1777-1779.
187. Moyer, A. M.; Salavaggione, O. E.; Hebbring, S. J.; Moon, I.; Hildebrandt, M. A.; Eckloff, B. W.; Schaid, D. J.; Wieben, E. D.; Weinshilboum, R. M. Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics. Clin. Cancer Res., 2007, 13(23), 7207-7216.
188. Agundez, J. A.; Ladero, J. M. Glutathione S-transferase GSTT1 and GSTM1 allozymes: beyond null alleles. Pharmacogenomics, 2008, 9(3), 359-363.
189. Miners, J. O.; Mackenzie, P. I. Drug glucuronidation in humans. Pharmacol. Ther., 1991, 51(3), 347-369.
190. Iyer, L.; Hall, D.; Das, S.; Mortell, M. A.; Ramirez, J.; Kim, S.; Di Rienzo, A.; Ratain, M. J. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther., 1999, 65(5), 576-582.
191. Ando, Y.; Saka, H.; Ando, M.; Sawa, T.; Muro, K.; Ueoka, H.; Yokoyama, A.; Saitoh, S.; Shimokata, K.; Hasegawa, Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res., 2000, 60(24), 6921-6926.
192. Posner, J.; Cohen, A. F.; Land, G.; Winton, C.; Peck, A. W. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome). Br. J. Clin. Pharmacol., 1989, 28(1), 117-120.
193. Tuteja, S.; Pyrsopoulos, N. T.; Wolowich, W. R.; Khanmoradi, K.; Levi, D. M.; Selvaggi, G.; Weisbaum, G.; Tzakis, A. G.; Schiff, E. R. Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. Pharmacotherapy, 2008, 28(9), 1188-1193.
194. Yoshigae, Y.; Konno, K.; Takasaki, W.; Ikeda, T. Characterization of UDP-glucuronosyltransferases (UGTS) involved in the metabolism of troglitazone in rats and humans. J. Toxicol. Sci., 2000, 25(5), 433-441.
195. King, C.; Tang, W.; Ngui, J.; Tephly, T.; Braun, M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol. Sci., 2001, 61(1), 49-53.
196. Kumar, R. S.; Ponmozhi, M.; Viswanathan, P.; Nalini, N. Effect of Cassia auriculata leaf extract on lipids in rats with alcoholic liver injury. Asia Pac. J. Clin. Nutr., 2002, 11(2), 157-163.
197. Martignoni, E.; Cosentino, M.; Ferrari, M.; Porta, G.; Mattarucchi, E.; Marino, F.; Lecchini, S.; Nappi, G. Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Neurology, 2005, 65(11), 1820-1822.
198. Garcia-Martin, E.; Ayuso, P.; Martinez, C.; Agundez, J. A. Improved analytical sensitivity reveals the occurrence of gender-related variability in diamine oxidase enzyme activity in healthy individuals. Clin. Biochem., 2007, 40(16-17), 1339-1341.
199. Ayuso, P.; Garcia-Martin, E.; Martinez, C.; Agundez, J. A. Genetic variability of human diamine oxidase: occurrence of three nonsynonymous polymorphisms and study of their effect on serum enzyme activity. Pharmacogenet Genomics, 2007, 17(9), 687-693.
200. Garcia-Martin, E.; Ayuso, P.; Martinez, C.; Blanca, M.; Agundez, J. A. Histamine pharmacogenomics. Pharmacogenomics, 2009, 10(5), 867-883.
201. Garcia-Martin, E.; Mendoza, J. L.; Martinez, C.; Taxonera, C.; Urcelay, E.; Ladero, J. M.; de la Concha, E. G.; Diaz-Rubio, M.; Agundez, J. A. Severity of ulcerative colitis is associated with a polymorphism at diamine oxidase gene but not at histamine N-ethyltransferase gene. World J. Gastroenterol., 2006, 12(4), 615-620.
202. Garcia-Martin, E.; Garcia-Menaya, J.; Sanchez, B.; Martinez, C.; Rosendo, R.; Agundez, J. A. Polymorphisms of histamine-etabolizing enzymes and clinical manifestations of asthma and allergic rhinitis. Clin. Exp. Allergy, 2007, 37(8), 1175-1182.
203. Garcia-Martin, E.; Ayuso, P.; Luengo, A.; Martinez, C.; Agundez, J. A. Genetic variability of histamine receptors in patients with Parkinson's disease. BMC Med. Genet., 2008, 9(15.
204. Garcia-Martin, E.; Martinez, C.; Serrador, M.; Alonso-Navarro, H.; Navacerrada, F.; Agundez, J. A.; Jimenez-Jimenez, F. J. Histamine-N-methyl transferase polymorphism and risk for migraine. Headache, 2008, 48(9), 1343-1348.
205. Agundez, J. A.; Luengo, A.; Herraez, O.; Martinez, C.; Alonso-Navarro, H.; Jimenez-Jimenez, F. J.; Garcia-Martin, E. Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson's disease. Neuromolecular Med., 2008, 10(1), 10-16.
206. Garcia-Martin, E.; Martinez, C.; Benito-Leon, J.; Calleja, P.; Diaz-Sanchez, M.; Pisa, D.; Alonso-Navarro, H.; Ayuso-Peralta, L.; Torrecilla, D.; Agundez, J. A.; Jimenez-Jimenez, F. J. Histamine-Nmethyl transferase polymorphism and risk for multiple sclerosis. Eur. J. Neurol., 2009.
207. Zhou, S. F.; Xue, C. C.; Yu, X. Q.; Wang, G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr. Drug Metab., 2007, 8(6), 526-553.
208. Hellum, B. H.; Hu, Z.; Nilsen, O. G. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin. Pharmacol. Toxicol., 2009, 105(1), 58-63.